新辅助化疗后MRI对结直肠癌腹膜转移分期的诊断效能
单中心回顾性研究纳入33例结直肠癌或阑尾来源腹膜转移接受新辅助化疗后行弥散加权MRI和手术的患者,两位放射科医师评估MRI腹膜癌指数(mriPCI),以手术PCI为参考标准。两位读者均正确识别全部23例可切除患者,10例不可切除患者中两位读者各检出8例;结论认为弥散加权MRI是新辅助化疗后重新评估腹膜癌指数的有前景工具。
要点
- 两位读者均正确识别全部23例可切除患者,10例不可切除患者中各检出8例。
核心结论
- 弥散加权MRI是新辅助化疗后重新评估腹膜癌指数的有前景工具。
研究设计与样本
- 单中心回顾性研究,纳入2016年1月至2021年2月接受新辅助化疗后行弥散加权MRI和手术的结直肠癌或阑尾来源腹膜转移患者33例,两位放射科医师评估再分期MRI的腹膜癌指数(mriPCI),以手术PCI(sPCI)为参考标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
INTRODUCTION: MRI improves the selection of patients with colorectal cancer (CRC) and peritoneal metastases (PM) for cytoreductive surgery by accurately assessing the extent of PM reflected as the peritoneal cancer index (PCI). The performance of MRI after neoadjuvant chemotherapy (NACT) for staging PM, however is unknown. The purpose of this study was to determine whether MRI could also accurately determine the PCI after NACT.
MATERIALS AND METHODS: This was a single-centre, retrospective study of patients with PM from CRC or appendiceal origin who received NACT followed by diffusion-weighted (DW)-MRI and surgery from January 2016 to February 2021. Two radiologists assessed the PCI on restaging DW-MRI (mriPCI). The reference standard was the surgical PCI (sPCI). The main outcome was the diagnostic performance of restaging DW-MRI in predicting whether patients were eligible for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), defined as a PCI < 21 with metastases on resectable locations. If CRS-HIPEC was performed, the resected peritoneal lesions were assessed and correlated with the final pathological PCI (pPCI).
RESULTS: Thirty-three patients were included. Both readers correctly detected all 23 patients with resectable disease. Eight out of ten patients with unresectable disease during staging surgery were detected by both readers with MRI. The intraclass correlation (ICC) between both readers was excellent (0⋅87 (95% CI: 0⋅75 to 0⋅93)). The ICC between pPCI and mriPCI was 0⋅74 (0⋅49-0⋅88) and 0⋅82 (0⋅66-0⋅91) for the 2 readers. Surgical PCI (sPCI) had a similar correlation as mriPCI with pPCI 0⋅82 (0⋅62- 0⋅92)) and 0⋅81 (0⋅57-0⋅92)).
CONCLUSION: DW-MRI is a promising tool to reassess the peritoneal cancer index after neoadjuvant chemotherapy.
引用
- Rijsemus, Kok, Aalbers, et al. Diagnostic performance of MRI for staging peritoneal metastases in patients with colorectal cancer after neoadjuvant chemotherapy. Eur J Radiol. 2022. PMID: 35255321. doi:10.1016/j.ejrad.2022.110225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。